Alzheimer disease therapy--moving from amyloid-β to tau. (Q38161786)

30 August 2017

Alzheimer disease therapy--moving from amyloid-β to tau. (English)

1 reference

30 August 2017

0 references

Ezio Giacobini

1

1 reference

30 August 2017

Gabriel Gold

series ordinal

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

12 November 2013

1 reference

30 August 2017

Nature Reviews Neurology

1 reference

30 August 2017

9

1 reference

30 August 2017

12

1 reference

30 August 2017

677-686

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2013.223

30 August 2017

0 references

cites work

Alzheimer's disease: the amyloid cascade hypothesis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Why so few drugs for Alzheimer's disease? Are methods failing drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Increasing the success rate for Alzheimer's disease drug discovery and development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Testing times for the "amyloid cascade hypothesis".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Solanezumab for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Enhanced proteolytic clearance of plasma Aβ by peripherally administered neprilysin does not result in reduced levels of brain Aβ in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Clinical validity of A beta-protein deposition staging in brain aging and Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Clinical validity of Braak neuropathological staging in the oldest-old

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Functional network disruption in the degenerative dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Animal models of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

A population-based clinicopathological study in the oldest-old: the 90+ study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Alzheimer disease pathology and longitudinal cognitive performance in the oldest-old with no dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Brain β-amyloid load approaches a plateau

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Brain injury biomarkers are not dependent on β-amyloid in normal elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Brain amyloid-β oligomers in ageing and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Has the amyloid cascade hypothesis for Alzheimer's disease been proved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Probing the biology of Alzheimer's disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Propagation of tau pathology in a model of early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Therapeutic strategies for tau mediated neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Tau-targeted treatment strategies in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

A feasibility and tolerability study of lithium in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

One hundred years after the discovery of Alzheimer's disease. A turning point for therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

γ-Secretase modulator in Alzheimer's disease: shifting the end.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.223

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

31 March 2020

1 reference

12 December 2020

Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.

1 reference

12 December 2020

Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

1 reference

12 December 2020

Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice

1 reference

12 December 2020

Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria.

1 reference

12 December 2020

Maintaining cognitive function in Alzheimer disease: how effective are current treatments?

1 reference

12 December 2020

10.1038/NRNEUROL.2013.223

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

0 references

1 reference